L-type calcium channel Ca V 1.2 plays an essential role in cardiac function. The gain-of-function mutations in Ca V 1.2 have been reported to be associated with Timothy syndrome, a disease characterized by QT prolongation and syndactyly. Previously we demonstrated that roscovitine, a cyclin-dependent kinase (CDK) inhibitor, could rescue the phenotypes in induced pluripotent stem cell-derived cardiomyocytes from Timothy syndrome patients. However, exactly how roscovitine rescued the phenotypes remained unclear. Here we report a mechanism potentially underlying the therapeutic effects of roscovitine on Timothy syndrome cardiomyocytes. Our results using roscovitine analogs and CDK inhibitors and constructs demonstrated that roscovitine exhibits its therapeutic effects in part by inhibiting CDK5. The outcomes of this study allowed us to identify a molecular mechanism whereby Ca V 1.2 channels are regulated by CDK5. This study provides insights into the regulation of cardiac calcium channels and the development of future therapeutics for Timothy syndrome patients.
INTRODUCTION
L-type calcium channel Ca V 1.2 plays an essential role in cardiac development and function (Flucher and FranziniArmstrong, 1996; Seisenberger et al., 2000) . The missense mutations in CACNA1C encoding Ca V 1.2 channel are associated with Timothy syndrome (TS), a multisystem disorder that features long-QT syndrome and syndactyly (Boczek et al., 2015; Hennessey et al., 2014; Papineau and Wilson, 2014; Splawski et al., 2004) . TS patients are treated clinically with b-adrenergic blockers, calcium channel blockers, and sodium channel blockers (Jacobs et al., 2006; Shah et al., 2012) . However, these regimens are insufficient to prevent lethal arrhythmias in TS patients (Corona-Rivera et al., 2015; Kawaida et al., 2016; Philipp and Rodriguez, 2016) . Therefore, new therapeutics for TS are still needed. Previously, we found that roscovitine, a cyclin-dependent kinase (CDK) inhibitor, could rescue the phenotypes in human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (CMs) and neurons from TS patients (Pasca et al., 2011; Song et al., 2015; Yazawa et al., 2011) . However, the mechanisms whereby roscovitine restores the cardiac functions in TS CMs have not been fully elucidated. In this study, we sought to investigate the mechanisms underlying the beneficial effects of roscovitine on TS CMs and to identify additional therapeutic compounds for TS.
RESULTS

Roscovitine Analog and CDK Inhibitor Tests
To confirm the cause of this disease and obtain ideal controls for the TS iPSCs, we generated isogenic control iPSCs from the TS iPSCs using TALEN (transcription activatorlike effector nuclease) technology, and characterized the isogenic control iPSCs ( Figure S1 ). The isogenic control iPSCs demonstrated a normal karyotype and pluripotency, and the CMs derived from the isogenic control iPSCs showed regular calcium transients in calcium imaging and normal voltage-dependent inactivation percentage values in voltage-clamp recordings, which are comparable with the values in CMs derived from non-isogenic control iPSCs generated from skin fibroblasts of healthy donors (Figures S1A-S1J). To search for roscovitine analogs that are more potent or less toxic than roscovitine and explore the mechanisms underlying the effects of roscovitine on TS CMs, we tested 20 roscovitine analogs and four CDK inhibitors with different specificities against CDKs using a contraction assay with MATLAB-based analysis (Huebsch et al., 2015; Yazawa et al., 2011) and calcium imaging (Figure 1A) . Two rounds of chemical test were conducted to examine the effects of the compounds. The first round of chemical testing was conducted using TS CM clusters isolated from the monolayer CMs to screen and identify the positive compounds that could increase the spontaneous beating rate and decrease the contraction irregularity of the TS CM clusters Table S1 ). The subsequent test was conducted using the intact monolayer CMs to validate the beneficial effects of the positive compounds on TS CMs and to eliminate the potential bias that could be caused by isolating the CMs from the original culture ( Figures 1B-1D ). From the chemical tests, we identified two roscovitine analogs, CR8 and Myoseverin-B, and two CDK inhibitors, PHA-793887 and DRF053, that had beneficial effects on TS CMs (Figures 1B-1D and S2; Table S1 ; Movie S1). When we summarized the CDK targets of all positive compounds, it was found that four out of the five positive compounds have been reported to inhibit CDK5 (Bettayeb et al., 2008; Brasca et al., 2010; Meijer et al., 1997; Oumata et al., 2008) (Figures 1B, S2G, and S2H) , suggesting that CDK5 could be involved in the molecular mechanisms underlying TS.
The Effects of CDK5 Inhibition on TS CMs
To examine whether CDK5 inhibition is beneficial for TS CMs, we first constructed a lentivirus containing the dominant negative (DN) mutant of CDK5. We used patch-clamp recordings and calcium imaging to assess the physiological properties of the TS CMs infected with the CDK5 DN lentivirus. The phenotypes of TS CMs include a delayed voltage-dependent inactivation of Ca V 1.2 channels, abnormal action potentials, and abnormal calcium transients (Song et al., 2015; Yazawa et al., 2011) . The TS CMs with CDK5 DN expression demonstrated a significantly enhanced voltage-dependent inactivation of Ca V 1.2 channels compared with the CMs without CDK5 DN expression (Figures 2A-2C) . Moreover, the expression of CDK5 DN significantly shortened the paced action potential duration and rescued the abnormal spontaneous action potentials in TS CMs ( Figures 2D, 2E , S3A, and S3B; Table S3 ). In addition, we examined the effects of CDK5 DN expression on the calcium currents in TS CMs. The results suggest that TS CMs demonstrated more late calcium currents compared with control CMs, and the expression of CDK5 DN significantly reduced the late calcium currents in TS CMs ( Figures S3C-S3E ). Finally, CDK5 DN expression alleviated the abnormal spontaneous calcium transients and paced calcium transients, and significantly reduced the calcium transient duration and half decay time in the paced TS CMs . Overall, the results indicated that CDK5 DN expression could alleviate all the previously reported phenotypes in TS CMs.
Next, we examined the effect of roscovitine on the TS CMs infected with the CDK5 DN lentivirus, to investigate whether CDK5 inhibition partially accounts for the therapeutic effects of roscovitine on TS CMs. The results showed that roscovitine did not further enhance the voltagedependent inactivation of Ca V 1.2 in TS CMs with CDK5 DN expression, indicating that CDK5 DN expression is sufficient to rescue the delayed voltage-dependent inactivation of Ca V 1.2 in TS CMs (Figures 2K and 2L) .
To validate our findings using another approach, we designed short hairpin RNA (shRNA) lentiviral constructs that target CDK5 and confirmed the knockdown efficiency of the constructs ( Figures S4A-S4C ). We then infected TS CMs with the CDK5 shRNA lentivirus and examined the effects of CDK5 shRNA expression on the reported phenotypes in TS CMs. CDK5 shRNA expression significantly enhanced the voltage-dependent inactivation of Ca V 1.2 in TS CMs ( Figures 2M and 2N ). In addition, CDK5 shRNA expression alleviated the abnormal spontaneous calcium transients in TS CMs . The effects of CDK5 shRNA expression on TS CMs were thus Table S1 ). n.d., CDK targets are not yet determined. (C) Representative traces from the MATLABbased analysis of TS CM contractions before treatment and 2 hr after the treatment of 2 mM CR8.
(D) The analysis of contraction irregularity of TS CMs before treatment and 2 hr after the treatment of each positive compound (n = 10 for the chemical compounds and n = 5 for DMSO control from one TS iPSC line; the irregularity value after treatment was normalized to the corresponding irregularity value before treatment for each sample in each group). *p < 0.05, **p < 0.01; Student's t test, paired. Ros, roscovitine; Myo-B, myoseverin-B; PHA, PHA-793887. The replicates (n) are independent biological replicates from multiple rounds of experiments. See Table S2 for detailed information about the iPSC lines used for each experiment. similar to the effects of CDK5 DN expression on TS CMs, indicating that CDK5 inhibition is beneficial for TS CMs.
The Molecular Mechanism Underlying the Positive Effects of CDK5-Specific Inhibition on TS CMs
The positive effects of CDK5-specific inhibition on TS CMs prompted us to investigate its underlying mechanisms.
CDK5 has been reported to phosphorylate serine or threonine in two consensus sequences, S/T-P-X-R/H/K and P-X-S/T-P (where X is any amino acid) (Dhariwala and Rajadhyaksha, 2008; Plattner et al., 2014) . We examined the sequences of Ca V 1.2 channels and found five consensus sequences located at the II-III loop and the C terminus (C-term), which are conserved in both humans and rodents 2+ currents in the TS CM with (+shRNA) and without (ÀshRNA) CDK5 shRNA expression. (N) Voltage-dependent inactivation percentage quantification in TS CMs with (n = 13) and without (n = 9) CDK5 shRNA expression. Data in (C), (E), (G-J), and (N) are mean ± SEM. Data were from two lines and Student's t test was used for statistics unless otherwise stated. n.s., not significant; *p < 0.05, **p < 0.01, ***p < 0.005. The replicates (n) are independent biological replicates from multiple rounds of experiments. See Table S2 for detailed information about the iPSC lines used for each experiment.
( Figure 3A ). We generated plasmids containing FLAGtagged full-length Ca V 1.2 and YFP-tagged CDK5 for a co-immunoprecipitation (coIP) assay. The coIP results demonstrated a binding of CDK5 with Ca V 1.2 ( Figure 3B ). Next, we generated FLAG-tagged II-III loop and FLAGtagged C-term of Ca V 1.2 constructs to repeat the coIP assay, and validated the binding of CDK5 with the two fragments ( Figure 3C ).
To examine whether CDK5 phosphorylates Ca V 1.2, we designed an in vitro kinase assay. The wild-type II-III loop or the C-term of Ca V 1.2 was used as the substrates in this assay. We generated mutant II-III loop and mutant C-term constructs with substitutions of serine/threonine to glycine or alanine in all CDK5 consensus sequences as negative controls ( Figures S4G and S4H) . The phosphorylation of the substrates by CDK5 consumes ATP and produces ADP, which is then converted into luminescence by detection reagents in the assay ( Figure 3D ). The luminescence signal was reduced when we added the CDK5 inhibitor, PHA-793887, to the reactions using wild-type II-III loop Figure 3 . Direct Interaction and Phosphorylation between CDK5 and Ca V 1.2 (A) The structure of human Ca V 1.2/a1c subunit. The G406R mutation and five CDK5 consensus sequences in Ca V 1.2 are shown.
(B and C) Co-immunoprecipitation (IP) was performed using FLAG antibody resins with HEK 293T cell lysates expressing YFP-CDK5 and FLAG-Ca V 1.2 (B), or FLAG-II-III loop (C), or FLAG-carboxyl terminus (C-term, C). Anti-(a-)human CDK5 and FLAG-tag antibodies were used for immunoblotting (IB). (D) Design of the in vitro kinase assay. The phosphorylation of the substrates by activated CDK5 consumes ATP and produces ADP that is converted into luminescence. (E and F) Wild-type (WT) II-III loop (II-III) and C terminus (C-term) were phosphorylated by CDK5. PHA-793887 (PHA) and the mutagenesis (II-III Mutant [MT]: S783G; C-term 4MT: S1742A/S1799A/ S1882A/T1958A) blocked the phosphorylation (II-III: n = 3 for both PHA groups and n = 6 for WT and MT groups; C-term: n = 6 for both PHA groups and n = 9 for WT and MT groups). **p < 0.01, Student's t test for WT versus MT/4MT; data are mean ± SEM. (G) Representative recordings of Ba 2+ currents in control CM with and without CDK5 WT overexpression. (H) CDK5 WT overexpression significantly delayed the voltage-dependent inactivation of Ca V 1.2 in control CMs (n = 14 for ÀCDK5 WT group and n = 12 for +CDK5 WT group from two control lines; **p < 0.01, Student's t test; data are mean ± SEM). (I) Representative Ca 2+ transient traces of control CMs infected with the R-GECO1 lentivirus and the YFP lentivirus (n = 24 from two lines) or the YFP-CDK5 WT lentivirus (n = 20 from two lines). y Axis, DF/F 0 for R-GECO1 (calcium fluorescence indicator). The replicates (n) are independent biological replicates from multiple rounds of experiments. See Table S2 for detailed information about the iPSC lines used for each experiment.
or C-term as the substrates. Moreover, the luminescence signal was significantly reduced when using mutant II-III loop or C-term as the substrates, compared with using wild-type II-III loop or C-term as the substrates in the kinase reactions. The results indicated the phosphorylation of the II-III loop and the C-term of Ca V 1.2 by CDK5 in vitro ( Figures 3E and 3F) . The remaining signals in the mutant II-III loop and C-term could result from the phosphorylation of p35 by CDK5 (Asada et al., 2012) and/or nonspecific phosphorylation of some serine/threonine residues in the mutant II-III loop and C-term. To provide additional support for the in vitro biochemical results, we examined whether wild-type CDK5 overexpression alters Ca V 1.2 channel functions in control CMs. We observed that wild-type CDK5 overexpression significantly delayed the voltage-dependent inactivation of Ca V 1.2 (Figures 3G and 3H) and induced abnormal calcium transients in control CMs ( Figure 3I ). Taken together, the results demonstrated that CDK5 potentially affects Ca V 1.2 functions by direct binding and phosphorylation, and that CDK5 overexpression could result in delayed voltage-dependent inactivation of Ca V 1.2 in control CMs.
To further explore the signaling pathways underlying the effects of CDK5 inhibition on TS CMs, we measured the mRNA expression of CDK5 and its activator p35 (CDK5R1) and p39 (CDK5R2) in control and TS CMs. We found a significant increase in the mRNA expression of p35 (CDK5R1) in TS CMs compared with controls ( Figures  4A and 4B ). We next measured the expression of EGR1, a transcription factor that regulates p35 transcription (Harada et al., 2001; Shah and Lahiri, 2014) , and observed a significant increase in EGR1 mRNA expression in TS CMs ( Figure 4C ). We found that the increased p35 (CDK5R1) mRNA expression led to an increased p35 protein expression and a hyperactivation of CDK5 in TS CMs . We then examined the protein expression of ERK (Harada et al., 2001; Shah and Lahiri, 2014) , the upstream regulator of EGR1. The results showed that the expression of phosphorylated ERK was increased in TS CMs, indicating an elevated ERK activity (Figures 4D and S4K) . Previous reports have established a connection between an increased intracellular calcium concentration and ERK activation in CMs (Wheeler-Jones, 2005; ZarainHerzberg et al., 2011) . Therefore, one of the potential mechanisms in TS CMs is that excessive calcium influx through the mutant Ca V 1.2 channels causes an increase in ERK activity, resulting in a subsequent induction of EGR1 and an increase in p35 expression. The increased expression of p35 causes CDK5 hyperactivation, which enhances the delayed inactivation of the mutant Ca V 1.2 channels, leading to more severe phenotypes in the TS CMs. Thus, CDK5 inhibition using CDK5 inhibitors, DN, or shRNA alleviates the phenotypes in TS CMs ( Figure 4E ).
DISCUSSION
In this study, we used human CMs derived from the iPSCs generated from the skin fibroblasts of two TS patients to identify additional potential therapeutic compounds based on roscovitine, our previously reported lead compound for TS (Song et al., 2015; Yazawa et al., 2011) . We tested the hypothesis that the beneficial effects of roscovitine on TS CMs are associated with its inhibitory effect on CDKs. We revealed a role of CDK5 in the pathogenesis of TS and a mechanism underlying the therapeutic effects of roscovitine on Figure 4 . One of the Potential Mechanisms Underlying the Effects of CDK5 Inhibition on TS CMs (A-C) GAPDH was used to normalize CDK5, CDK5R1 (p35), CDK5R2 (p39), and EGR1 expression in the qPCR analysis (*p < 0.05, **p < 0.01; Student's t test; data are mean ± SEM). CM samples from four control lines (Ctrl, n = 12 for CDK5, CDK5R1, CDK5R2, and n = 9 for EGR1 including two isogenic control lines) and two TS lines (TS, n = 14 for CDK5, CDK5R1, CDK5R2 and n = 9 for EGR1) were tested. (D) Phosphorylated ERK (pERK) and p35 proteins were increased in TS CMs compared with control (Ctrl) CMs. (E) Schematic presentation of the proposed signaling pathway in TS CMs. The replicates (n) for this figure are independent biological replicates from multiple rounds of experiments. See Table S2 for detailed information about the iPSC lines used for each experiment.
TS CMs, whereby roscovitine exhibits its effects in part by inhibiting CDK5. Roscovitine has been reported to enhance the voltage-dependent inactivation of Ca V 1.2 with the TS mutation in a heterologous overexpression system (Yarotskyy and Elmslie, 2007; Yarotskyy et al., 2009 Yarotskyy et al., , 2010 . Compared with the heterologous system, using TS CMs derived from iPSCs allowed us to examine the effects of roscovitine in a more physiologically relevant cardiac environment. Patient-specific iPSCs provided us with the opportunity to identify key mediators such as CDK5, which is involved in the regulation of Ca V 1.2 channels in CMs. Although there are several recent updates that provide insights into the structural and functional changes in the Ca V 1.2 channels caused by the TS mutations (Dick et al., 2016; Li et al., 2016 ) and a few previous reports indicating the potential regulation of Ca V 1.2 by CDK5 in pancreatic b cells and a neuronal progenitor cell line (Furusawa et al., 2014; Wei et al., 2005) , our findings demonstrate that CDK5 plays an important role in regulating Ca V 1.2 functions in CMs and that the inhibition of CDK5 is beneficial for TS CMs.
There are still some concerns in the studies using human iPSC-based disease models, one of which is that patientspecific iPSC-based models of long-QT syndrome demonstrate relatively prolonged action potentials (Itzhaki et al., 2011) relative to the patients' QT intervals. Thus, the iPSC-derived CMs do not fully respond to physiologically relevant high pacing frequencies (1-2 Hz) in calcium imaging and action potential recordings. Another concern is that there might be a progression in the disease phenotypes in iPSC-based models of long-QT syndrome over time, and it would be difficult to identify the optimal time points to examine the effects of therapeutic candidates in the patient-specific CMs (See Supplemental Note).
Although we found the role of CDK5 in cardiac calcium channel regulation, exactly how CDK5 regulates Ca V 1.2 channels via phosphorylation in the II-III loop and C-term remains unclear. Therefore, further investigation is necessary to elucidate the molecular mechanisms by which CDK5 phosphorylates and regulates Ca V 1.2 channels in CMs. Moreover, based on the consensus sequences targeted by CDK5, CDK5 may have effects on the functions of other ion channels such as HCN4 and Nav1.5, which play important roles in cardiac function. This report provides insights into the molecular bases of cardiac calcium channel regulation and the development of future therapeutics for TS patients.
EXPERIMENTAL PROCEDURES
In brief, human iPSCs were cultured using a standard feeder-free protocol with Essential 8 medium and Geltrex (Thermo-Fisher/Life Technologies) following the manufacturer's instructions. Human control and patient iPSC lines were differentiated into CMs using the monolayer-based in vitro differentiation protocol (Song et al., 2015 (2015) . Novel Timothy syndrome mutation leading to increase in CACNA1C window current. Heart Rhythm 12, 211-219.
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Wei, F.Y., Nagashima, K., Ohshima, T., Saheki, Y., Lu, Y.F., Matsushita, M., Yamada, Y., Mikoshiba, K., Seino, Y., Matsui, H., et al. (2005) . Cdk5-dependent regulation of glucose-stimulated insulin secretion. Nat. Med. 11, 1104-1108. (n=9), two isogenic control iPSC lines (n=22) and two Timothy syndrome (TS) iPSC lines (n=11). The parameters were comparable between the CMs derived from the non-isogenic control iPSCs and the isogenic control iPSCs (n.s. not significant. **P<0.01, ***P<0.005, ****P<0.001; One-way ANOVA with Bonferroni post-hoc; Data are mean ± s.e.m.). (E) RT-PCR to confirm the expression of NANOG in isogenic control clones. The non-specific band of NANOG has been shown previously with the same primer set (Song et al., 2015) . (F) Representative voltage-clamp recordings of Ba 2+ currents in single CM derived from non-isogenic control iPSCs or isogenic control iPSCs. "1.0 (relative)" means that the data points were normalized to the corresponding peak current value to make the traces. (G, H) The current-voltage relationship and voltage-dependent inactivation percentage value quantification in CMs derived from isogenic control iPSCs and non-isogenic control iPSCs (n=12 for the isogenic control group from three lines and n=10 for the non-isogenic control group from two lines. Student's t-test; n.s. not significant). (I) The isogenic control iPSCs demonstrated normal karyotype. (J) Teratoma formation with isogenic control clones. The hematoxylin and eosin staining demonstrated all three germ layers. Scale bar, 100μm. The replicates (n) are independent single cell biological replicates. See Table S2 for the detailed information of the iPSC lines used for each experiment. The analysis of the beating rate of TS CM clusters before treatment and 24 hours after the treatment of each compound (n=24 for Ros, n=11 for CR8, n=12 for Myo-B, n=10 for PHA, n=11 for NSC43067 and n=17 for PD0332991 from one TS patient line. *P<0.05, ***P<0.005, ****P<0.001; Student's t-test, paired). The beating rate value after treatment was normalized to the corresponding beating rate value before treatment for each sample in each group. Note that DRF053 compound was directly tested on monolayer TS CMs but not on TS CM clusters. (C) The analysis of the contraction irregularity of TS CMs before treatment and 24 hours after the treatment of each compound (n=16 for Ros, n=6 for CR8, n=10 for Myo-B, n=9 for PHA, n=10 for NSC43067 and n=6 for PD0332991 from one TS patient line. *P<0.05; Student's t-test, paired). The irregularity value after treatment was normalized to the corresponding irregularity value before treatment for each sample in each group. Note that the DRF053 compound was directly tested on monolayer TS CMs but not on TS CM clusters. See also or mutant (4MT: S1742A/S1799A/S1882A/T1958A) C-term. Anti-(α-) human CDK5 and FLAG-tag antibodies were used for immuno-blotting (IB). Mutagenesis does not have any significant effect on the binding affinity of CDK5 to II-III loop and C-term. (H) The dose-response curve of PHA-793887 on the luminescence signal from the in vitro kinase assay with wild-type II-III loop as the substrates. The curve reached a plateau phase from the dose of 5μM PHA-793887 and there was a stable background luminescence signal in the kinase assay. Therefore, the luminescence values from the reactions using the wild-type substrates (II-III loop or C-term) with the addition of 5μM PHA-793887 were used to normalize the background in Figure 3E and Figure 3F . Data are mean ± s.d. (I) Endogenous CDK5 activity in CMs derived from control (Ctrl) iPSCs, embryonic stem cell line H9 and TS iPSCs. TS CMs demonstrated a significantly higher CDK5 activity compared with control CMs (n=11 for Ctrl, n=9 for H9 and n=9 for TS; *P<0.05, **P<0.01; n.s., not significant; One-way ANOVA with Bonferroni post-hoc; Data are mean ± s.e.m.). (J) 5 μM PHA-793887 (PHA) addition significantly reduced CDK5 activity in TS CM samples in the endogenous CDK5 activity assay (n=9 for TS group and n=8 for TS with PHA group; ***P<0.005; Student's t-test; Data are mean ± s.e.m.). Data were normalized to the average value from TS CM samples without PHA addition. (K) The full western blot images of the cropped images showed in Figure 4D . The p35 band was determined according to the molecular weight and the band position of p35 in the previous pilot immunoblotting experiments. The molecular weight of the nonspecific band in this blotting of p35 was over 79 kDa and the band was not shown in the films with shorter exposure times. The replicates (n) are independent biological replicates from multiple rounds of experiments. See Table S2 for the detailed information of the iPSC lines used for each experiment. Table S1 . Summary of Roscovitine analog test, related to Figure 1 and Figure S2 . Movie S1. Monolayer Timothy syndrome cardiomyocytes before the treatment of 2μM CR8 and two hours after the treatment of 2μM CR8. The movies were used for the contraction irregularity analysis in Figure 1D . Table S2 . Detailed information of the iPS cell lines used for each experiment, related to all Figures.
Clone TS1-E3-5 was derived from one TS patient (TS1). Clone TS2-E6-2 and TS2-E7-1 were derived from another TS patient (TS2). Clone IM-E1-5 was derived from Human embryonic lung fibroblast IMR90 (ATCC). Clone NH-E1-1 and NH-E5-4 were derived from normal adult human dermal fibroblasts (NHDF, Life Technologies).
We confirmed that the data from clone TS1-E3-5 and TS2-E7-1 derived from two TS patients are homogeneous and the data from the two clones are combined as TS group in the experiments. We confirmed the data from the clone IM-E1-5, NH-E1-1 and NH-E5-4 derived from two commercially available healthy fibroblasts are homogeneous and the data from some of the clones are combined as control group in the experiments. We confirmed that cardiomyocytes derived from isogenic control iPSC clones were comparable to cardiomyocytes derived from non-isogenic control clones. In some experiments, the cardiomyocytes differentiated from isogenic control clones and non-isogenic control clones were both used as control group.
The detailed generation/characterization of the iPSC clones, the cardiac differentiation method and the use of the calcium indicator R-GECO1 for calcium imaging have been reported previously (Song et al., 2015) . The names of each iPSC clones described here are the same with our previous publication.
Experiment Figure number The information of the cell lines used for the experiment Contraction assay Figure 1D TS monolayer cardiomyocytes were differentiated from clone TS1-E3-5. Voltage-clamp recording & paced action potential recording Figure 2A -2E &Figure 2K-2N TS cardiomyocytes were differentiated from clone TS1-E3-5 and TS2-E7-1. Control cardiomyocytes were differentiated both from clone IM-E1-5 and NH-E5-4 and from an embryonic stem cell line H9. The samples were collected from three rounds of differentiation and viral infection. Calcium imaging Figure 2F -2J &Figure S3I-S3L TS cardiomyocytes were differentiated from clone TS1-E3-5 and TS2-E7-1. The samples were collected from three rounds of differentiation and viral infection. Voltage-clamp recording Figure 3G&3H The control cardiomyocytes differentiated from clone IM-E1-5 and NH-E5-4 were used. The samples were collected from four rounds of differentiation and viral infection. Calcium imaging Figure 3I The control cardiomyocyte clusters differentiated from clone IM-E1-5 and NH-E1-1 were used. The samples were collected from two rounds of differentiation and viral infection. Quantitative PCR Figure 4A -4C Control cardiomyocyte samples were collected from cardiomyocytes differentiated from non-isogenic iPSC clone IM-E1-5 and NH-E1-1, and isogenic control iPSC clone 1 and clone 2 that were generated from the TS iPSC clones (TS1-E3-5 and TS2-E7-1). TS cardiomyocyte samples were differentiated from clone TS1-E3-5 and TS2-E7-1. Western blot analysis Figure 4D & Figure  S4K The experiments were repeated four times with different samples to examine p35 protein expression. The control cardiomyocyte samples were collected from clone IM-E1-5, NH-E1-1, and isogenic control clone 1. The TS cardiomyocyte samples were collected from clone TS1-E3-5 and TS2-E7-1. The experiments were repeated three times with different samples to examine ERK and phosphorylated ERK protein expression. The control cardiomyocyte samples were collected from clone IM-E1-5, NH-E5-4, and isogenic control clone 4. The TS cardiomyocyte samples were collected from clone TS1-E3-5 and TS2-E7-1. Consistent results were found in the experiments and representative images from one of the experiments were shown. Calcium imaging Figure S1C -S1D Control cardiomyocytes were differentiated from clone IM-E1-5 and NH-E5-4. Isogenic control cardiomyocytes were differentiated from isogenic control clone 1 and clone 2 that were generated from the TS iPSC clones (TS1-E3-5 and TS2-E7-1). TS cardiomyocyte samples were differentiated from clone TS1-E3-5 and TS2-E7-1. Voltage-clamp recording Figure S1F -S1H Control cardiomyocytes were differentiated from clone IM-E1-5 and NH-E5-4. Isogenic control cardiomyocytes were differentiated from isogenic control clone 1, clone 2 and clone 4 that were generated from the TS iPSC clones (TS1-E3-5 and TS2-E7-1). Contraction assay Figure S2A -S2C TS cardiomyocyte clusters were differentiated from clone TS1-E3-5. Calcium imaging Figure S2D -S2F TS cardiomyocytes were differentiated from clone TS1-E3-5 and TS2-E7-1. Spontaneous action potential recording & calcium current recording Figure S3A -S3B, Figure S3C -S3E TS cardiomyocytes were differentiated from clone TS1-E3-5 and TS2-E7-1. Control cardiomyocytes were differentiated both from clone IM-E1-5 and NH-E5-4 and from an embryonic stem cell line H9. The samples were collected from three rounds of differentiation and viral infection. Calcium imaging Figure S3F -S3H& Figure S3M TS cardiomyocytes were differentiated from clone TS1-E3-5, TS2-E6-2 and TS2-E7-1. The samples were collected from three rounds of differentiation and viral infection. Calcium imaging Figure S4D -S4F& Figure S3M TS cardiomyocytes were differentiated from clone TS1-E3-5 and TS2-E7-1. The samples were collected from three rounds of differentiation and viral infection. CDK5 activity assay Figure S4I & S4J TS cardiomyocytes were differentiated from clone TS1-E3-5 and TS2-E7-1. Control cardiomyocytes were differentiated both from clone IM-E1-5 and NH-E5-4 and from an embryonic stem cell line H9. The samples were collected from four rounds of differentiation and the experiments were conducted four times. Figure 2D and 2E.
Supplemental experimental procedures:
Cell culture:
Control and Timothy syndrome induced pluripotent stem cells (iPSCs) were generated using a virus-free method from the skin fibroblasts and characterized as described previously (Song et al., 2015) . Mycoplasma tests were conducted using MycoAlert (Lonza) when the iPSC lines were generated. Human embryonic stem cell (ESC) line H9 (#WA09, NIH cell line code #0062) was obtained from WiCell Research Institute, Inc. (August 8th, 2014, Agreement # 15-W0039) as an additional control human pluripotent stem cell line. iPSCs or the ESC line H9 were cultured with Essential 8 media with 100 unit/ml penicillin and 100 μg/ml streptomycin on plates or dishes (Corning) coated with Geltrex (#A14133-022, from Life Technologies) following the manufacturer's instruction. The iPSC lines or the ESC line H9 were maintained and passaged following the previously-reported protocol using dispase (Life technologies) (Song et al., 2015) . Human iPSC-derived cardiomyocytes were maintained in EB5 media: DMEM/F12 medium with GlutaMAX (Life Technologies) containing 5 % fetal bovine serum (FBS, Hyclone, Thermo Scientific), 1mM non-essential amino acids (Life Technologies), 0.1mM beta-mercaptoethanol (Sigma-Aldrich), 100 unit/ml penicillin and 100 μg/ml streptomycin. Human embryonic kidney (HEK) 293T cells (ATCC) and 293Ta cells (Lenti-Pac, GeneCopoeia) were cultured in Dulbecco's Modified Eagle Media (DMEM) (Life Technologies) supplemented with 10% FBS, 2mM L-glutamine (Life Technologies), 100 unit/ml penicillin and 100 μg/ml streptomycin. All cells were cultured in HERAcell 150i (Thermo Scientific) incubators and culture procedures were conducted in the Biosafety Cabinet Class II type A2 tissue culture hoods (Labconco).
The generation of isogenic controls:
The transcription activator-like (TAL) sequences for the isogenic control generation were synthesized using the service from Life
technologies. The ordered TAL binding sequences were TCCCTTCCTACGGCATCAT corresponding to RVD (T)-HD-HD-HD-NG-NG-HD-HD-NG-NI-HD-NN-NN-HD-NI-NG-HD-NI-NG for hCACNA1C_TAL_R, and TGCCTCACTAACTATCATT corresponding to RVD (T)-NN-HD-HD-NG-HD-NI-HD-NG-NI-NI-HD-NG-NI-NGHD-NI-NG-NG
for hCACNA1C_TAL_L, where '(T)' indicates that the first binding repeat that is provided by the vector. The synthetic hCACNA1C_TAL_L and hCACNA1C_TAL_R were assembled from synthetic oligonucleotides and/or PCR products. Based on the manufacturer's protocol, the fragments were cloned into TALtrunc_FokI using 100% sequence verified subfragments. The resulting plasmids were purified from transformed bacteria and quantified by UV spectroscopy (Nanovue Plus, G.E. Healthcare Life Sciences).
The final constructs were confirmed by sequencing. The synthesized TAL sequences were released from the original vectors by digesting the vectors with NotI and HindIII. The isolated synthesized TAL sequences were sub-cloned into a pEF1a_MCS vector digested with NotI and HindIII. The pEF1a_MCS_TALEN_L and pEF1a_MCS_TALEN_R vectors were purified from transformed bacteria and quantified by UV spectroscopy. The final constructs were confirmed by sequencing. The donor DNA was cloned from the genomic DNA of a control iPSC line using the PCR reaction with Phusion polymerase (Thermo Scientific), a standard Phusion PCR protocol, and the primer set: Forward 5'-GTGCACATGAACAAAGCCCACGTTCAG-3'; Reverse 5'-GCCCGGTTACTTCTACCACTTCTAACTTC-3'. The PCR product (1.2 kb) was purified using the QIAquick PCR purification kit (Qiagen) and the sequence was confirmed by sequencing to match the normal CACNA1C gene sequence. The TALEN L plasmid, TALEN R plasmid, donor DNA and a green fluorescent protein (GFP) plasmid (pmaxGFP ® from Lonza or AAVS1-CAG-hrGFP, Addgene: #52344) were transduced into Timothy syndrome iPSCs cultured in 6 well plates at the ratio of 15:15:1:5 (3.6 μg DNA/well) using transfection with Lipofectamine LTX with an optimized protocol described previously (Song et al., 2015) . The GFP positive cells were sorted out using CCTI flow cytometry service at Columbia University and returned to culture in a hypoxia incubator (5% oxygen) for recovery. The recovered clones were expanded and stocked. Genomic DNA from each clone was isolated using DNeasy
Blood and Tissue Kit (Qiagen) and the region encoding CACNA1C exon 8a was amplified using Phusion polymerase PCR and the primer set: Forward 5'-TACACTAATCAT CATAGGGTCAT-3'; Reverse 5'-TAGCGATTCCCAGTTTAGGTAC-3'. The PCR product (1.2 kb) was purified using the QIAquick PCR purification kit (Qiagen) and directly sequenced using the original forward primer and a new reverse primer (Ori-R-MY): 5'-CTCAGAGATAGACTGCTCAGTCTATG-3'. Positive clones from the screen were expanded and adapted to normoxia incubator (20% oxygen) for following experiments. For isogenic control generation, we used three Timothy syndrome patient lines (clone#: TS1-E3-5, TS2-E6-2 and TS2-E7-1) derived from two independent patients and picked up 91 single cell clones for screening. We obtained 91 single cell clones using the protocol described above. Among the 91 clones, we identified 9 isogenic control clones in total from TS1-E3-5 and TS2-E7-1. No positive clone was identified from the 8 clones recovered from TS2-E6-2 following the protocol described above. Overall, the success rate is 9.9%. We used the isogenic control clone 1, 2, 3, 4 and 5 for gene expression profiling. We used clone 1, 2, 3 and 4 for karyotyping. We used the cardiomyocytes differentiated from clone 1 and clone 2 for calcium imaging and qPCR. We used the cardiomyocytes differentiated from clone 1, clone 2 and clone 4 for electrophysiological recordings. We used the cardiomyocytes differentiated from clone 1 and clone 4 for western blot experiments as described in Table S2 .
The characterization of isogenic control iPSCs:
The karyotyping of isogenic control iPSCs was performed by WiCell (Wisconsin). For the RT-PCR of NANOG using the primer set (Forward 5'-CAGCCCCGATTCTTCCACCAGTCCC-3' and Reverse 5'-CGGAAGATTCCCAGTCGGGTTCACC-3'), RNA from the isogenic control iPSCs was prepared using the RNeasy Mini kit and RNase-Free DNase set (Qiagen). cDNA was synthesized from 1 μg RNA using the SuperScript III First-Strand Synthesis System for RT-PCR (Life Technologies). The cDNA (21 μl) was diluted with DNase-free water (Invitrogen) at 1:5 and 1 μl of the samples was used for conventional RT-PCR with Ex taq (Clontech/TaKaRa Bio). The teratoma formation assays were performed following the previously-reported protocol (Song et al., 2015) and the H.E.
staining was performed by the pathological staining service at Columbia University. For the teratoma formation assays, two 8-week-old severe combined immunodeficient (SCID) beige male mice (Charles River Laboratories) were used for each line and the teratoma formation was observed in all mice that were injected with the iPSCs. All animal protocols and handling for the teratoma formation assay were performed following the guidelines established by Columbia Institutional Animal Care and Use Committee under our approved protocol (for LJ.S. and M.Y., #AC-AAAF5655). To examine the differentiation potentials of the isogenic control iPS lines used for further experiments, cardiac differentiation was conducted as reported previously (Song et al., 2015) . The calcium transients of the cardiomyocytes derived from isogenic control iPSCs, non-isogenic control iPSCs and Timothy syndrome iPSCs were imaged with the genetically encoded indicator R-GECO1 as reported previously (Song et al., 2015) . The Ba 2+ current recordings were obtained from the cardiomyocytes derived from isogenic control iPSCs and non-isogenic control iPSCs with the procedure and the protocol described in the electrophysiology method section.
Preparation of chemical compounds:
(R)-Roscovitine (Purity: ≥ 98% (HPLC)) and the Roscovitine analogs (R)-CR8 (Purity: ≥ 95% (HPLC)), Myoseverin B (Purity: ≥ 97% (HPLC)), Purvalanol A (Purity: ≥ 98% (HPLC)), Purvalanol B (Purity: ≥ 97% (HPLC)), Olomoucine (Purity: ≥ 98% (HPLC)), N 9 -Isopropylolomoucine (Purity: ≥ 98% (HPLC)) and Bohemine (Purity: ≥ 95% (HPLC)) were purchased from Sigma Aldrich and all the rest of the Roscovitine analogs (13 in total) were purchased from ChemBridge Corp. The ChemBridge compounds with 7-digit name were from EXPRESS-Pick™ Collection for which the minimum purity was 90% and the identity was confirmed using 1H-NMR and/or LC-MS/ELSD. The ChemBridge compounds with 8-digit name were from the CORE Library for which the minimum purity was 85% and the identity was confirmed using LC-MS/ELSD. (R)-Roscovitine was dissolved in DMSO (dimethyl sulfoxide, Sigma-Aldrich, #276855-100ML). Except for Bohemine that was dissolved in methanol following manufacturer's instruction, all the other Roscovitine analogs were dissolved in DMSO. For the cyclin-dependent kinase (CDK) inhibitors, PD0332991
(Purity: ≥ 98% (HPLC)) and NSC43067 (Purity: ≥ 98% (HPLC)) were purchased from Sigma Aldrich. (R)-DRF053 (Purity: ≥ 98% (HPLC)) was purchased from Abcam and PHA-793887 (Purity: ≥ 98% (HPLC)) was purchased from ApexBio. Except for PD0332991 that was dissolved in sterile distilled water, all the other CDK inhibitors were all dissolved in DMSO. The stock concentration for (R)-Roscovitine was 5mM and the stock concentration of all the other chemical compounds was 10mM. All the stock solutions were stored at -80 o C and thawed only once after made.
The analysis of cardiomyocyte contractions for compound tests:
The working solution of each compound was made by diluting the stock solution in EB5 media to a final concentration of 5 μM except for (R)-CR8, which was diluted to a final concentration of 1 or 2 μM. 0.1% or less DMSO (or methanol) did not have any significant effects on the phenotypes in Timothy syndrome cardiomyocytes. The contraction analysis was performed as reported previously (Yazawa et al., 2011) . In brief, images were collected at a rate of 5 frames per second using the NIS-elements software (Nikon) and converted to multi-frame TIFF images for analysis using the NIS-elements viewer. The multiple-frame TIFF images were processed using the Image Processing Toolbox in MATLAB R2009b (Mathworks). Relative motion between successive frames was quantified by subtracting each frame from the preceding frame and summing across all pixels. Movement was calculated by plotting the relative motion over time. Contractions were detected as a peak of relative motion and a second, typically smaller peak, corresponded to the relaxation of the cardiomyocytes. Peaks were selected manually and the rate of contraction was measured. The length of time between contractions was also measured and contraction irregularity was measured by calculating the ratio of the standard deviation to the mean of the intervals between contractions. The Timothy syndrome cardiomyocytes were used for the tests at day 21-22 after cardiac differentiation. The movies were taken before the treatment, and 24 hours after the treatment of each compound from the Timothy syndrome cardiomyocyte clusters in the first round of test for Roscovitine analogs and CDK inhibitors. The movies were taken before the treatment, and 2 hours after the treatment of each positive compound from the intact monolayer Timothy syndrome cardiomyocytes for a second round of test to validate positive compounds. The compound DRF053 was directly tested in intact monolayer Timothy syndrome cardiomyocytes in the second round of test but it was not tested in the first round of test. The cardiomyocytes from one Timothy syndrome iPSC line (clone#: TS1-E3-5) were used mainly for the tests and the cardiomyocytes from another independent Timothy syndrome iPSC line (clone#: TS2-E7-1) were used for validation. The contraction rate and the irregularity of each sample before and after treatment were compared using paired Student's t-test. The contraction rate and irregularity value of each sample after treatment were normalized to its respective value before treatment in the corresponding figures.
Plasmid construction and the preparation of lentiviruses:
The CDK5 cDNA was amplified from the cDNA samples of a control iPSC line using Phusion polymerase (Thermo Scientific) and with primer sets that allowed us to add restriction enzyme site NotI and Kozak sequence before the start codon and another site XhoI after the stop codon. The fragment was subcloned into a pcDNA3 vector (Invitrogen) that was digested with NotI and XhoI for the following generation of CDK5 WT and CDK5 dominant negative (DN) lentiviruses. For the generation of CDK5 dominant negative mutant (DN), the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent) was used to generate the mutation leading to the D144N mutation in CDK5 protein. The plasmid containing the CDK5 DN or CDK5 WT was used as the templates to amplify the CDK5 DN or CDK5 WT sequence using Phusion polymerase and the primer sets that allowed us to add restriction enzyme site EcoRI and Kozak sequence before the start codon and another site XhoI after the stop codon. The PCR products were subcloned into lentiviral vector that was prepared from LV-SD-Cre (Addgene, #12105, no longer available currently) digested with EcoRI and XhoI. XL-10 Gold competent cells (Agilent) transformed with the lentiviral LV-SD vectors were inoculated at 24-30 o C. The purified LV-SD vectors were transfected together with pCMV-dR8.2 dvpr and pCMV-VSV-G (Addgene #8455 & 8454) into HEK 293T cells for lentiviral production, following a protocol described previously (Song et al., 2015) . The shRNA constructs for CDK5 were purchased from GeneCopoeia along with the Lenti-Pac FIV Expression Packaging Kit (FPK-LvTR-40). The knockdown efficiency of the shRNAs was examined and the scrambled shRNA (as a control) lentivirus and CDK5 shRNA lentivirus were prepared in the lentiviral 293Ta packaging cells (Lenti-Pac, #CLv-PK-01) purchased from GeneCopoeia, following the manufacturer's instructions. The shRNA lentiviruses were concentrated 6 folds using the Lenti-X concentrator (Clontech) following the manufacturer's instructions to infect the Timothy syndrome cardiomyocytes.
The FLAG-tagged full-length rat CaV1.2 plasmid, the FLAG-II-III loop plasmid and the FLAG-C-terminus plasmid were generated using conventional sub-cloning method using Phusion and PCR primers in pcDNA3 vector as described above. The QuikChange II XL Site-Directed Mutagenesis Kit was used to introduce the mutation(s) to the FLAG-II-III loop plasmid and the FLAG-C-terminus plasmid leading to S783G mutation in the II-III loop amino acid sequence and S1742A/S1799A/S1882A/T1958A mutations in the C-terminus amino acid sequence.
Electrophysiology:
The control and Timothy syndrome iPSCs were differentiated into cardiomyocytes following a protocol reported previously (Song et al., 2015) . The cell clusters were isolated from the monolayer cardiomyocytes and re-plated into gelatin-coated wells in 6-well plates at day 16. For the experiments to examine the effects of CDK5 DN expression in Timothy syndrome cardiomyocytes, the cells were infected with the YFP-CDK5 DN lentivirus at day 19-21 after differentiation. For the experiments to examine the effects of CDK5
shRNA expression in Timothy syndrome cardiomyocytes, the cells were infected with CDK5 shRNA lentivirus at day 19-21 after differentiation. The CDK5 shRNA lentiviruses were concentrated using the lenti-X concentrator (Clontech) by 6 folds. The cells were dissociated into single cells for whole-cell patch clamp recordings at day 31 to 36 and plated into 35mm glass bottom culture dishes (7mm diameter No. 1.5 glass, MatTek, #P35G-1.5-7-C) coated with Geltrex. The patch-clamp recordings using cardiomyocytes infected with CDK5 DN construct were performed between day 35 and day 42 after differentiation while recordings using cardiomyocytes infected with CDK5 shRNA construct were conducted between day 40 and day 47. Whole-cell patch clamp recordings of iPSC-derived cardiomyocytes were conducted using a MultiClamp 700B patch-clamp amplifier (Molecular Devices) and an inverted microscope equipped with differential interface optics (Nikon, Ti-U). The glass pipettes were prepared using borosilicate glass (Sutter Instrument, BF150-110-10) using a micropipette puller (Sutter Instrument, Model P-97). Voltage-clamp measurements were conducted at room temperature (~24 o C) using an extracellular solution consisting of 5mM BaCl2, 160mM TEA-Cl and 10mM HEPES (pH7.4 at 25 o C) and a pipette solution of 125mM CsCl, 0.1mM CaCl2, 10mM EGTA, 1mM MgCl2, 0.3mM
TrisGTP and 10mM HEPES (pH 7.4 adjusted with CsOH at 25 o C). For calcium current recording, another extracellular solution was used: 5mM CaCl2, 137mM NMDG, 0.5 mM MgCl2, 25mM CsCl, 10mM TEA-Cl, 10mM glucose, and 10mM HEPES (pH7.4
adjusted with HCl at 25 o C). Two pulse protocols were used. One protocol was that cells were held at -90mV and then depolarized to -10mV for 400 ms at a rate of 0.1 Hz for the Ba 2+ current recordings. The other protocol was that cells were held at -90mV and depolarized to -50mV for 2 seconds to eliminate the T-type current contamination, and then depolarized to +10/-10mV for 400 ms at a rate of 0.1 Hz for the Ca 2+ /Ba 2+ current recordings to measure the L-type current; cells were held at -90 mV, stimulated with a 2-s family of pulses from -90 to +50/+20mV for the current-voltage relationship of the Ca 2+ /Ba 2+ currents. The recordings were conducted under room temperature.
The voltage-dependent inactivation (percentage) is defined as the Ba 2+ current intensity at 350ms from the peak divided by the peak current intensity in Figure 2B , Figure 2N , Figure 3H and Figure S1G . The late calcium current percentage is defined as the calcium current intensity at 350ms from the peak divided by the peak current intensity in Figure S3D . The data points to plot the representative traces in Figure 2A , Figure 2M , Figure 3G and Figure S1F were normalized to the respective peak current value of the trace and therefore labeled as "1.0 (relative)". The values used to plot the current-voltage relationship of the Ba 2+ current recordings ( Figure 2C) and Ca 2+ current recordings ( Figure S3E ) were normalized to their respective peak current value before being used for the grouped analysis. In Figure 2L , Current-clamp recordings were conducted in normal Tyrode solution containing 140mM NaCl, 5.4mM KCl, 1mM MgCl2, 10mM glucose, 1.8mM CaCl2 and 10mM HEPES (pH7.4 with NaOH at 25 o C) using the pipette solution: 120mM K D-gluconate, 25mM
KCl, 4mM MgATP, 2mM NaGTP, 4mM Na2-phospho-creatin, 10mM EGTA, 1mM CaCl2 and 10mM HEPES (pH 7.4 with HCl at 25 o C). The recordings were conducted at 37 o C. Cardiac action potentials were stimulated (5ms, 0.3nA) in current clamp mode at 37 o C (0.2 Hz). First, we paced the patient cardiomyocytes at 0.5 Hz or 1 Hz for action potential recordings and we found that the cardiomyocytes could not respond the pacing frequencies due to the prolonged action potential phenotype (>2 seconds). Therefore, we decided to use lower pacing frequency (0.2 Hz) and examined the effects of CDK5 DN expression on the paced action potentials in Timothy syndrome cardiomyocytes. Recorded action potentials were analyzed using Clampfit 10.4 (Axon Instruments). The spontaneous action potential duration (action potential duration at 50% of repolarization (APD50) and action potential duration at 90% of repolarization (APD90)) values from the Timothy syndrome cardiomyocytes with CDK5 DN expression in Figure S3B were normalized to the values from the Timothy syndrome cardiomyocytes without CDK5 DN expression, and therefore the Y-axis title was labeled as "Relative action potential duration".
Calcium imaging and the analysis of calcium transient traces:
The Timothy syndrome iPSCs, non-isogenic control iPSCs and isogenic control iPSCs were differentiated into cardiomyocytes following a protocol reported previously (Song et al., 2015) . The cell clusters were isolated from the monolayer cardiomyocytes and re-plated into gelatin-coated wells in 6-well plates at day 16 after differentiation. For the calcium imaging of the cardiomyocyte clusters derived from the non-isogenic control iPSCs, isogenic control iPSCs or Timothy syndrome iPSCs, and the cardiomyocyte clusters infected with the yellow fluorescent protein (YFP) lentivirus or the YFP-CDK5 WT lentivirus, the clusters were transferred to glass-bottom dishes (7mm diameter, No. 1.5 glass) coated with Geltrex at day 23 and the calcium imaging was conducted following the protocol described previously (Song et al., 2015) between day 25 to day 31. For the single cell imaging of the cardiomyocytes derived from the isogenic control iPSCs, the cell clusters were dissociated into single cells at day 40 and the imaging was conducted following the protocol described previously (Song et al., 2015) at day 43 and day 44. For the single cell imaging of the Timothy syndrome cardiomyocytes infected with the YFP lentivirus or the YFP-CDK5 DN lentivirus, the cells were infected with the lentiviruses of R-GECO1, a genetically encoded calcium indicator, and other corresponding lentiviral constructs at day 19-21 and dissociated into single cells at day 31 after differentiation. The calcium imaging was conducted following the protocol described previously (Song et al., 2015) between day 35 and day 42. For the single cell imaging of the Timothy syndrome cardiomyocytes infected with the R-GECO1 lentivirus and scrambled shRNA lentivirus or CDK5 shRNA lentivirus, the cells were infected with the R-GECO1 lentiviruses and other corresponding constructs at day 19-21 and dissociated into single cells at day 36 after differentiation.
The scrambled shRNA or CDK5 shRNA lentiviruses were concentrated using the lenti-X concentrator (Clontech) by 6-fold and therefore it took one extra week for the cells to recover from the viral infection. The calcium imaging was conducted following the protocol described previously (Song et al., 2015) between day 40 and day 47. In brief, the Nikon Ti-U epi-fluorescent microscope were analyzed using the Graphpad prism software.
For the paced calcium transient recordings to examine the effects of PHA-793887 on the abnormal calcium transients in Timothy syndrome cardiomyocytes, the Timothy syndrome cardiomyocytes were isolated from the monolayer culture and re-plated into gelatin-coated wells in 6-well plates at day 16 after differentiation. The cells were dissociated at day 28 after differentiation and used for calcium imaging between day 31 to day 35. The Nikon automatic microscope with CO2 (5%) and temperature control (37 o C) were used for this experiment. Nikon objective lens 40x was used for single cell recordings and the EB5 media was used as bath solution.
The stimulus isolation unit and perfusion insert with electric field stimulation for 35mm dish were used for electrical pacing. The For western blot analysis, the cardiomyocytes were collected at day 26 or day 27 after differentiation and lysed with the cell lysis buffer containing 1% Triton X-100, 50mM Tris-HCl, 150mM NaCl, 250mM sucrose, 1x protease inhibitor cocktail, 1x phosphatase inhibitor cocktail 3 (Catalog # P0044, Sigma-Aldrich) and 1x phosphatase inhibitor cocktail (Catalog # P8340, Sigma-Aldrich), pH 7.4. The cell lysates were frozen with liquid nitrogen immediately and stored at -80 o C. On the day of the western blot experiment, the samples were thawed on ice and the concentration of total proteins in each sample was measured using a standard bicinchoninic acid (BCA) assay kit (Pierce Biotechnology). Next, 20 μg of proteins from each sample were aliquoted and denatured with the sample buffer containing Urea and being boiled for 5 minutes at 95 o C. The samples were loaded to the Tris-HCl based SDS-PAGE gels with 5% stacking gel and 10% separation gel along with the ladder. The proteins were electro-transferred to PVDF-membranes using the XCell SureLock TM Mini-Cell system overnight. Next day, the membranes were blocked with the SuperBlock Blocking for 30 minutes at RT and incubated with the primary antibody (diluted in the SuperBlock Blocking buffer) overnight at 4 o C. On the third day, the membranes were incubated with the corresponding secondary antibody (1:8,000 dilution in the SuperBlock Blocking buffer) for 30 minutes at RT and then incubated with the Pierce ECL western blotting substrate followed by exposing to X-ray films in a dark room.
For sequential immunoblotting, the membranes were stripped with the stripping buffer containing 62.5mM Tris-HCl, 2% SDS, 114mM
beta-mercaptoethanol at 42 o C for 15-20 minutes, and washed six times with PBS. The stripped membranes were then re-blocked with SuperBlock Blocking Buffer for the next immunoblotting. For the immunoblotting of beta-tubulin, the membrane was stripped, re-blocked with the SuperBlock Blocking Buffer and incubated with the beta-tubulin antibody at RT for 30 minutes. The rest of the steps were the same. The western blot analysis to examine p35 expression in control and Timothy syndrome cardiomyocytes were repeated four times with independent samples for validation. The western blot analysis to examine the expression of ERK and phosphorylated ERK in control and Timothy syndrome cardiomyocytes were repeated three times with independent samples for validation.
In vitro kinase assay:
To prepare the substrates, the HEK 293T cells were plated at the density of 2 million/dish in 100mm dishes and transfected with 18 μg of the plasmid containing the FLAG-tagged wild-type ( μM, 5 μM, 50 μM and 500 μM) of PHA-793887 were tested and a dose-response curve was shown in Figure S4H . The relative ATP-ADP conversion values (luminescence) that were normalized to the values from the reactions using WT fragments as substrates were used to make Figure 3E and Figure 3F . Two rounds of independent experiments were conducted for the data in Figure 3E and three rounds of independent experiments were conducted for the data in Figure 3F .
In vitro CDK5 activity assay:
For the test of chemical compounds (Ros, CR8, PHA and Myo-B) on CDK5 activity, the CDK5 activity assay was conducted following the manufacturer's protocol (CDK5/p35 kinase enzyme system, Catalog # V3271, ADP-Glo TM kinase assay, Catalog # V9101, Promega) with some modifications. The reaction mixes contain 1 μg Histone H1 (substrate), 1X Reaction Buffer A, 50 μM DTT, 50 μM ATP, 0.1 μg CDK5/p35 and 1ul compound solution or pure DMSO in distilled water. The compounds (Roscovitine, CR8, PHA-793887, DRF053 and Myoseverin B) were made and diluted as stock solutions in DMSO at different concentrations before testing. The final dose for Roscovitine, CR8, PHA-793887 and DRF053 in the reaction mix was 50nM and Myoseverin-B were tested at the dose of 50nM, 500nM, 1 μM, 10 μM, 100 μM, 1mM and 5mM. DMSO was added to the control (Ctrl) reaction mixes. The final concentration of DMSO for every reaction mix was 1%. A series of samples for a standard curve were prepared based on the manufacturer's instructions to determine the ATP-ADP conversion from the luminescence signals in every round of experiment. The kinase reaction tubes with the reaction mixes were incubated at 26-27 o C for 60 minutes for the kinase reaction. The ADP-Glo with an integration time of 1.5s. The luminescence values were converted into the ATP-ADP conversion values based on the standard curve. The ATP-ADP conversion values normalized to control group (Luminescence) were used for data analysis in Figure S2G and Figure S2H .
To examine the endogenous CDK5 activity, an CDK5 activity assay was conducted following the previous reported protocols (Bu et al., 2002; Hallows et al., 2003) with some modifications. iPSC-derived cardiomyocytes differentiated from control iPSCs, embryonic stem cell line H9 and Timothy syndrome iPSCs were collected at day 26 or day 27 for the assay. Cardiomyocytes were isolated from monolayer culture and lysed with the cell lysis buffer containing 1% NP-40, 20mM Tris-HCl, 137mM NaCl, 1x protease inhibitor cocktail, 1x phosphatase inhibitor cocktail 3 and 1x phosphatase inhibitor cocktail, pH 7.4. The protein concentration in the samples was measured using a standard bicinchoninic acid (BCA) assay kit. 40 μg of proteins from each sample were aliquoted and used as one were conducted. The values from each round of experiments were normalized to the average value of the control cardiomyocyte samples before being pooled together for the final analysis that is showed in Figure S4I . The values from each round of experiments were normalized to the average value of the Timothy syndrome cardiomyocyte samples without PHA addition before being pooled together for the final analysis that is showed in Figure S4J .
Quantitative RT-PCR:
RNA from the control and Timothy syndrome cardiomyocytes at day 19 after differentiation was prepared using the RNeasy Mini kit and RNase-Free DNase set (Qiagen). cDNA was synthesized using the SuperScript III First-Strand Synthesis System for RT-PCR GATGACATCAAGAAGGTGGTGA-3', Reverse 5'-GTCTACATGGCAACTGTGAGGA-3'. The CT value of each sample at 50% of the amplification curve was used and GAPDH was used to normalize the expression of CDK5, CDK5R1 (p35), CDK5R2 (p39) and EGR1. All the samples are biological repeats from two to three rounds of independent cardiac differentiation.
Statistical analysis:
The statistics used for every figure have been indicated in the corresponding figure legends. The Student's t-test (paired and unpaired)
was conducted with the t-test function in Microsoft Excel software. F-test was conducted before the t-test to determine whether the samples have equal variance in Microsoft Excel software. The Student's t-test was two tails. The One-way ANOVA with Bonferroni post-hoc or Dunnett's post-hoc analyses for multiple comparisons were conducted with the Graphpad prism software. All the data meet the assumptions of the statistical tests. All the samples used in this study were biological repeats, not technical repeats. We did not exclude any samples or results from the analysis in this study.
Supplemental note:
The calcium imaging experiment to examine the effects of CDK5 shRNA expression on Timothy syndrome cardiomyocytes was conducted at later time points than the time points for the calcium imaging experiment to examine the effects of CDK5 DN expression on Timothy syndrome cardiomyocytes. This was because the infection efficiency of the scrambled shRNA lentiviruses and the CDK5
shRNA lentiviruses was moderate and we concentrated the scrambled shRNA lentiviruses and the CDK5 shRNA lentiviruses to infect Timothy syndrome cardiomyocytes for calcium imaging. Thus it took one extra week for the cardiomyocytes to recover from the viral infection with 6-fold concentrated lentiviruses. The calcium imaging of the Timothy syndrome cardiomyocytes with scrambled shRNA or CDK5 shRNA expression was therefore conducted one week later than the calcium imaging of the Timothy syndrome cardiomyocytes infected with YFP or YFP-CDK5 DN expression. We found that the disease phenotype progressed over time and there was an increase in the average calcium transient half-decay time and the percentage of single Timothy syndrome cardiomyocyte with very prolonged calcium transients in the scrambled shRNA group, compared with the YFP group, in Figure S3 and Figure S4 . The beneficial effects of CDK5 inhibition and reduction on the abnormal calcium transients in Timothy syndrome cardiomyocytes were consistent, in spite of the different time points of the calcium imaging experiments.
